Methyprylon

Structural formula
	1: 1 mixture of ( R ) -methyprylon (left) and ( S ) -methyprylon (right)
General
Non-proprietary name	Methyprylon
other names	( RS ) -3,3-Diethyl-5-methyl-2,4-piperidinedione; (±) -3,3-Diethyl-5-methylpiperidine-2,4-dione ( IUPAC );
Molecular formula	C 10 H 17 NO 2
External identifiers / databases
EC number	204-745-4
ECHA InfoCard	100.004.315
PubChem	4162
DrugBank	DB01107
Wikidata	Q409558
Drug information
ATC code	N05 CE02
Drug class	Sedative, hypnotic
properties
Molar mass	183.26 g mol −1
Physical state	firmly
Melting point	84.5 ° C ( polymorphic )
solubility	soluble in water, ethanol , diethyl ether and chloroform
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS hazard labeling ; no classification available
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Methyprylon is a drug that has been used as a sedative and hypnotic . It was patented by Hoffmann-La Roche in 1954 and had been on the market in Germany under the trade name Noludar ^® since 1955.

From a chemical point of view, it belongs to the group of piperidinediones , just like glutethimide , pyrithyldione and thalidomide . These, in turn, are structural modifications of the barbiturates .

Mechanism of action

The duration of action of Methyprylon corresponds to that of medium-effective barbiturates. It has no advantages over these.

unwanted effects

Long-term use can lead to dependence .

Legal status

Methyprylon is listed in Appendix II of the German Narcotics Act and is therefore one of the marketable but not prescription narcotics.

literature

Entry to Methyprylon. In: Römpp Online . Georg Thieme Verlag, accessed on January 2, 2015.
HJ Roth, H. Fenner: Medicines . Thieme, Stuttgart a. New York, 1988. pp. 270-271.

Individual evidence

↑ ^a ^b H. PT Ammon (Hrsg.): Hunnius Pharmaceutical Dictionary . 9th edition, Walter de Gruyter, Berlin a. New York, 2004. pp. 987. ISBN 978-3-11-017475-5 .
↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
↑ Psychiatric Drugs Timeline

[Hunnius-1] H. PT Ammon (Hrsg.): Hunnius Pharmaceutical Dictionary . 9th edition, Walter de Gruyter, Berlin a. New York, 2004. pp. 987. ISBN 978-3-11-017475-5 .

[NV-2] This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.

[3] Psychiatric Drugs Timeline